标题
RAF-MEK-ERK pathway in cancer evolution and treatment
作者
关键词
MAPK, RAF, MEK, ERK, Cancer
出版物
SEMINARS IN CANCER BIOLOGY
Volume -, Issue -, Pages -
出版商
Elsevier BV
发表日期
2021-05-14
DOI
10.1016/j.semcancer.2021.05.010
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- B-Raf autoinhibition in the presence and absence of 14-3-3
- (2021) Mingzhen Zhang et al. STRUCTURE
- Mutant-selective degradation by BRAF-targeting PROTACs
- (2021) Shanique Alabi et al. Nature Communications
- Direct targeting of oncogenic RAS mutants with a tumor-specific cytosol-penetrating antibody inhibits RAS mutant–driven tumor growth
- (2020) Seung-Min Shin et al. Science Advances
- Structure–activity relationship study of DEL-22379: ERK dimerization inhibitors with increased safety
- (2020) Yang Yang et al. MOLECULAR DIVERSITY
- ERK signalling: a master regulator of cell behaviour, life and fate
- (2020) Hugo Lavoie et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Differences and similarities between cancer and somatic stem cells: therapeutic implications
- (2020) Fiorella Rossi et al. Stem Cell Research & Therapy
- Regulation of apoptosis in health and disease: the balancing act of BCL-2 family proteins
- (2019) Rumani Singh et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Targeting Alterations in the RAF–MEK Pathway
- (2019) Rona Yaeger et al. Cancer Discovery
- Inflammatory side effects of BRAF and MEK inhibitors
- (2019) Anna G. Mackin et al. MELANOMA RESEARCH
- Regulation of c-Raf Stability through the CTLH Complex
- (2019) Christina McTavish et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Phosphorylation of TMEM55B by Erk/MAPK regulates lysosomal positioning
- (2019) Shinya Takemasu et al. JOURNAL OF BIOCHEMISTRY
- K27-linked ubiquitination of BRAF by ITCH engages cytokine response to maintain MEK-ERK signaling
- (2019) Qing Yin et al. Nature Communications
- ERK regulates HIF-1α-mediated platinum resistance by directly targeting PHD2 in ovarian cancer
- (2019) Zhuqing Li et al. CLINICAL CANCER RESEARCH
- Oncogenic BRAF Alterations and Their Role in Brain Tumors
- (2019) Felix Behling et al. Cancers
- ERK-dependent phosphorylation of the linker and substrate-binding domain of HSP70 increases folding activity and cell proliferation
- (2019) Semi Lim et al. EXPERIMENTAL AND MOLECULAR MEDICINE
- A patent review of RAF kinase inhibitors (2010–2018)
- (2019) Ruo-Jun Man et al. EXPERT OPINION ON THERAPEUTIC PATENTS
- Encorafenib, Binimetinib, and Cetuximab in BRAF V600E–Mutated Colorectal Cancer
- (2019) Scott Kopetz et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cryo-EM structure of a dimeric B-Raf:14-3-3 complex reveals asymmetry in the active sites of B-Raf kinases
- (2019) Yasushi Kondo et al. SCIENCE
- Targeting Oncogenic BRAF: Past, Present, and Future
- (2019) Zaman et al. Cancers
- BRAF Mutations and the Utility of RAF and MEK Inhibitors in Primary Brain Tumors
- (2019) Karisa C. Schreck et al. Cancers
- Therapeutic targeting of RAS: New hope for drugging the “undruggable”
- (2019) Imran Khan et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH
- ILF3 is a substrate of SPOP for regulating serine biosynthesis in colorectal cancer
- (2019) Kai Li et al. CELL RESEARCH
- Discovery of a Potent and Selective Oral Inhibitor of ERK1/2 (AZD0364) That Is Efficacious in Both Monotherapy and Combination Therapy in Models of Nonsmall Cell Lung Cancer (NSCLC)
- (2019) Richard A. Ward et al. JOURNAL OF MEDICINAL CHEMISTRY
- Dual-mechanism ERK1/2 inhibitors exploit a distinct binding mode to block phosphorylation and nuclear accumulation of ERK1/2
- (2019) Andrew M Kidger et al. MOLECULAR CANCER THERAPEUTICS
- Architecture of autoinhibited and active BRAF–MEK1–14-3-3 complexes
- (2019) Eunyoung Park et al. NATURE
- AZ304, a novel dual BRAF inhibitor, exerts anti-tumour effects in colorectal cancer independently of BRAF genetic status
- (2018) Rui Ma et al. BRITISH JOURNAL OF CANCER
- RSK Regulates PFK-2 Activity to Promote Metabolic Rewiring in Melanoma
- (2018) Thibault Houles et al. CANCER RESEARCH
- ERK Mutations and Amplification Confer Resistance to ERK-Inhibitor Therapy
- (2018) Bijay S. Jaiswal et al. CLINICAL CANCER RESEARCH
- Development of encorafenib for BRAF-mutated advanced melanoma
- (2018) Peter Koelblinger et al. CURRENT OPINION IN ONCOLOGY
- A Raf-Competitive K-Ras Binder Can Fail to Functionally Antagonize Signaling
- (2018) Monique J. Kauke et al. MOLECULAR CANCER THERAPEUTICS
- MK-8353: Discovery of an Orally Bioavailable Dual Mechanism ERK Inhibitor for Oncology
- (2018) Sobhana Babu Boga et al. ACS Medicinal Chemistry Letters
- Allele-Specific Mechanisms of Activation of MEK1 Mutants Determine Their Properties
- (2018) Yijun Gao et al. Cancer Discovery
- Ras/ERK-signalling promotes tRNA synthesis and growth via the RNA polymerase III repressor Maf1 in Drosophila
- (2018) Shrivani Sriskanthadevan-Pirahas et al. PLoS Genetics
- KLF4 Nuclear Export Requires ERK Activation and Initiates Exit from Naive Pluripotency
- (2018) Navroop K. Dhaliwal et al. Stem Cell Reports
- Four Key Steps Control Glycolytic Flux in Mammalian Cells
- (2018) Lukas Bahati Tanner et al. Cell Systems
- Small molecule inhibitors of RAS-effector protein interactions derived using an intracellular antibody fragment
- (2018) Camilo E. Quevedo et al. Nature Communications
- The E3 ubiquitin ligase HERC1 controls the ERK signaling pathway targeting C-RAF for degradation
- (2018) Taiane Schneider et al. Oncotarget
- Development of small-molecule therapeutics and strategies for targeting RAF kinase in BRAF-mutant colorectal cancer
- (2018) Jing-hua Pan et al. Cancer Management and Research
- Structural snapshots of RAF kinase interactions
- (2018) Soheila Rezaei Adariani et al. BIOCHEMICAL SOCIETY TRANSACTIONS
- ERK and miRNA-1 target Cx43 expression and phosphorylation to modulate the vascular protective effect of angiotensin II
- (2018) Yan Lei et al. LIFE SCIENCES
- Efficacy of a Covalent ERK1/2 Inhibitor, CC-90003, in KRAS-Mutant Cancer Models Reveals Novel Mechanisms of Response and Resistance
- (2018) Ida Aronchik et al. MOLECULAR CANCER RESEARCH
- RAF inhibitor PLX8394 selectively disrupts BRAF dimers and RAS-independent BRAF-mutant-driven signaling
- (2018) Zhan Yao et al. NATURE MEDICINE
- Therapeutic strategies to target RAS-mutant cancers
- (2018) Meagan B. Ryan et al. Nature Reviews Clinical Oncology
- Oncogenic KRAS supports pancreatic cancer through regulation of nucleotide synthesis
- (2018) Naiara Santana-Codina et al. Nature Communications
- A compendium of ERK targets
- (2017) Evrim B. Ünal et al. FEBS LETTERS
- Exceptionally high-affinity Ras binders that remodel its effector domain
- (2017) John H. McGee et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Heat Shock-induced Phosphorylation of TAR DNA-binding Protein 43 (TDP-43) by MAPK/ERK Kinase Regulates TDP-43 Function
- (2017) Wen Li et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Design and Discovery of N-(2-Methyl-5′-morpholino-6′-((tetrahydro-2H-pyran-4-yl)oxy)-[3,3′-bipyridin]-5-yl)-3-(trifluoromethyl)benzamide (RAF709): A Potent, Selective, and Efficacious RAF Inhibitor Targeting RAS Mutant Cancers
- (2017) Gisele A. Nishiguchi et al. JOURNAL OF MEDICINAL CHEMISTRY
- Discovery of a novel pan-RAF inhibitor with potent anti-tumor activity in preclinical models of BRAF V600E mutant cancer
- (2017) Sung Pyo Hong et al. LIFE SCIENCES
- BRAF-inhibitor Associated MEK Mutations Increase RAF-Dependent and -Independent Enzymatic Activity
- (2017) Caroline M. Emery et al. MOLECULAR CANCER RESEARCH
- ERK-Induced Activation of TCF Family of SRF Cofactors Initiates a Chromatin Modification Cascade Associated with Transcription
- (2017) Cyril Esnault et al. MOLECULAR CELL
- Current Development Status of MEK Inhibitors
- (2017) et al. MOLECULES
- Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS
- (2017) Zhan Yao et al. NATURE
- Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients
- (2017) Ahmet Zehir et al. NATURE MEDICINE
- AMPK: guardian of metabolism and mitochondrial homeostasis
- (2017) Sébastien Herzig et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- A brain-penetrant RAF dimer antagonist for the noncanonical BRAF oncoprotein of pediatric low-grade astrocytomas
- (2017) Yu Sun et al. NEURO-ONCOLOGY
- CRAF gene fusions in pediatric low-grade gliomas define a distinct drug response based on dimerization profiles
- (2017) P Jain et al. ONCOGENE
- Direct inhibition of RAS: Quest for the Holy Grail?
- (2017) Russell Spencer-Smith et al. SEMINARS IN CANCER BIOLOGY
- RAF inhibitors promote RAS-RAF interaction by allosterically disrupting RAF autoinhibition
- (2017) Ting Jin et al. Nature Communications
- First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study
- (2017) Ryan J. Sullivan et al. Cancer Discovery
- The APC/C E3 Ligase Complex Activator FZR1 Restricts BRAF Oncogenic Function
- (2017) Lixin Wan et al. Cancer Discovery
- Phosphorylation of β-arrestin2 at Thr383 by MEK underlies β-arrestin-dependent activation of Erk1/2 by GPCRs
- (2017) Elisabeth Cassier et al. eLife
- Quantification of spatiotemporal patterns of Ras isoform expression during development
- (2017) Anna U. Newlaczyl et al. Scientific Reports
- A Small Molecule RAS-Mimetic Disrupts RAS Association with Effector Proteins to Block Signaling
- (2016) Sai Krishna Athuluri-Divakar et al. CELL
- PKM2, cancer metabolism, and the road ahead
- (2016) Talya L Dayton et al. EMBO REPORTS
- A phase I pharmacokinetic and pharmacodynamic study of the oral mitogen-activated protein kinase kinase (MEK) inhibitor, WX-554, in patients with advanced solid tumours
- (2016) David Jamieson et al. EUROPEAN JOURNAL OF CANCER
- Discovery of (S)-1-(1-(4-Chloro-3-fluorophenyl)-2-hydroxyethyl)-4-(2-((1-methyl-1H-pyrazol-5-yl)amino)pyrimidin-4-yl)pyridin-2(1H)-one (GDC-0994), an Extracellular Signal-Regulated Kinase 1/2 (ERK1/2) Inhibitor in Early Clinical Development
- (2016) James F. Blake et al. JOURNAL OF MEDICINAL CHEMISTRY
- p90 ribosomal S6 kinase: a potential therapeutic target in lung cancer
- (2016) Noufira Poomakkoth et al. Journal of Translational Medicine
- Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial
- (2016) Paolo A Ascierto et al. LANCET ONCOLOGY
- A Novel RAF Kinase Inhibitor with DFG-Out-Binding Mode: High Efficacy in BRAF-Mutant Tumor Xenograft Models in the Absence of Normal Tissue Hyperproliferation
- (2016) I. C. Waizenegger et al. MOLECULAR CANCER THERAPEUTICS
- Small molecule stabilization of the KSR inactive state antagonizes oncogenic Ras signalling
- (2016) Neil S. Dhawan et al. NATURE
- Mutant Kras copy number defines metabolic reprogramming and therapeutic susceptibilities
- (2016) Emma M. Kerr et al. NATURE
- Preclinical efficacy of a RAF inhibitor that evades paradoxical MAPK pathway activation in protein kinaseBRAF-mutant lung cancer
- (2016) Ross A. Okimoto et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Early ERK1/2 activation promotes DRP1-dependent mitochondrial fission necessary for cell reprogramming
- (2016) Javier Prieto et al. Nature Communications
- Addiction to Coupling of the Warburg Effect with Glutamine Catabolism in Cancer Cells
- (2016) Bradley Smith et al. Cell Reports
- Phosphorylation acts positively and negatively to regulate MRTF-A subcellular localisation and activity
- (2016) Richard Panayiotou et al. eLife
- Magnolin inhibits cell migration and invasion by targeting the ERKs/RSK2 signaling pathway
- (2015) Cheol-Jung Lee et al. BMC CANCER
- Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers
- (2015) Sheng-Bin Peng et al. CANCER CELL
- Paradox-Breaking RAF Inhibitors that Also Target SRC Are Effective in Drug-Resistant BRAF Mutant Melanoma
- (2015) Maria Romina Girotti et al. CANCER CELL
- TP53 Silencing Bypasses Growth Arrest of BRAFV600E-Induced Lung Tumor Cells in a Two-Switch Model of Lung Tumorigenesis
- (2015) A. Shai et al. CANCER RESEARCH
- MEK Guards Proteome Stability and Inhibits Tumor-Suppressive Amyloidogenesis via HSF1
- (2015) Zijian Tang et al. CELL
- Advances in Molecular Biology of Lung Disease
- (2015) Claire Rooney et al. CHEST
- Crucial requirement of ERK/MAPK signaling in respiratory tract development
- (2015) O. Boucherat et al. DEVELOPMENT
- The RAF-MEK-ERK pathway: targeting ERK to overcome obstacles to effective cancer therapy
- (2015) Zutao Yu et al. Future Medicinal Chemistry
- The distribution ofBRAFgene fusions in solid tumors and response to targeted therapy
- (2015) Jeffrey S. Ross et al. INTERNATIONAL JOURNAL OF CANCER
- Discovery of 1-(3,3-Dimethylbutyl)-3-(2-fluoro-4-methyl-5-(7-methyl-2-(methylamino)pyrido[2,3-d]pyrimidin-6-yl)phenyl)urea (LY3009120) as a Pan-RAF Inhibitor with Minimal Paradoxical Activation and Activity against BRAF or RAS Mutant Tumor Cells
- (2015) James R. Henry et al. JOURNAL OF MEDICINAL CHEMISTRY
- Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial
- (2015) Georgina V Long et al. LANCET
- AMPK Promotes Aberrant PGC1β Expression To Support Human Colon Tumor Cell Survival
- (2015) Kurt W. Fisher et al. MOLECULAR AND CELLULAR BIOLOGY
- BRAF Inhibition Decreases Cellular Glucose Uptake in Melanoma in Association with Reduction in Cell Volume
- (2015) N. Theodosakis et al. MOLECULAR CANCER THERAPEUTICS
- BGB-283, a Novel RAF Kinase and EGFR Inhibitor, Displays Potent Antitumor Activity in BRAF-Mutated Colorectal Cancers
- (2015) Z. Tang et al. MOLECULAR CANCER THERAPEUTICS
- The Novel ATP-Competitive MEK/Aurora Kinase Inhibitor BI-847325 Overcomes Acquired BRAF Inhibitor Resistance through Suppression of Mcl-1 and MEK Expression
- (2015) M. S. Phadke et al. MOLECULAR CANCER THERAPEUTICS
- Mitochondrial Division Is Requisite to RAS-Induced Transformation and Targeted by Oncogenic MAPK Pathway Inhibitors
- (2015) Madhavika N. Serasinghe et al. MOLECULAR CELL
- MCRIP1, an ERK Substrate, Mediates ERK-Induced Gene Silencing during Epithelial-Mesenchymal Transition by Regulating the Co-Repressor CtBP
- (2015) Kenji Ichikawa et al. MOLECULAR CELL
- Erk2 Phosphorylation of Drp1 Promotes Mitochondrial Fission and MAPK-Driven Tumor Growth
- (2015) Jennifer A. Kashatus et al. MOLECULAR CELL
- RAF inhibitors that evade paradoxical MAPK pathway activation
- (2015) Chao Zhang et al. NATURE
- Regulation of RAF protein kinases in ERK signalling
- (2015) Hugo Lavoie et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- On being the right (cell) size
- (2015) M. B. Ginzberg et al. SCIENCE
- MEK1/2 Inhibitors: Molecular Activity and Resistance Mechanisms
- (2015) Pui-Kei Wu et al. SEMINARS IN ONCOLOGY
- Inhibition of ERK1/2 down-regulates the Hippo/YAP signaling pathway in human NSCLC cells
- (2015) Bin You et al. Oncotarget
- Management of BRAF and MEK inhibitor toxicities in patients with metastatic melanoma
- (2015) Sarah J. Welsh et al. Therapeutic Advances in Medical Oncology
- Dysfunctional oxidative phosphorylation makes malignant melanoma cells addicted to glycolysis driven by the V600EBRAF oncogene
- (2015) Arnaldur Hall et al. Oncotarget
- Klf2 Is an Essential Factor that Sustains Ground State Pluripotency
- (2014) Jia-Chi Yeo et al. Cell Stem Cell
- Diminished WNT -> -catenin -> c-MYC signaling is a barrier for malignant progression of BRAFV600E-induced lung tumors
- (2014) J. Juan et al. GENES & DEVELOPMENT
- Phase I study of XL281 (BMS-908662), a potent oral RAF kinase inhibitor, in patients with advanced solid tumors
- (2014) Mark A. Dickson et al. INVESTIGATIONAL NEW DRUGS
- Oncogenic and sorafenib-sensitive ARAF mutations in lung adenocarcinoma
- (2014) Marcin Imielinski et al. JOURNAL OF CLINICAL INVESTIGATION
- The Erk2 MAPK Regulates CD8 T Cell Proliferation and Survival
- (2014) W. N. D'Souza et al. JOURNAL OF IMMUNOLOGY
- A unique inhibitor binding site in ERK1/2 is associated with slow binding kinetics
- (2014) Apirat Chaikuad et al. Nature Chemical Biology
- Targeting RAS–ERK signalling in cancer: promises and challenges
- (2014) Ahmed A. Samatar et al. NATURE REVIEWS DRUG DISCOVERY
- ERK1 phosphorylates Nanog to regulate protein stability and stem cell self-renewal
- (2014) Sung-Hyun Kim et al. Stem Cell Research
- Receptor Tyrosine Kinases: Legacy of the First Two Decades
- (2014) J. Schlessinger Cold Spring Harbor Perspectives in Biology
- Response of BRAF-Mutant Melanoma to BRAF Inhibition Is Mediated by a Network of Transcriptional Regulators of Glycolysis
- (2014) T. J. Parmenter et al. Cancer Discovery
- Comprehensive Genomic Profiling of Pancreatic Acinar Cell Carcinomas Identifies Recurrent RAF Fusions and Frequent Inactivation of DNA Repair Genes
- (2014) J. Chmielecki et al. Cancer Discovery
- Erk Signaling Suppresses Embryonic Stem Cell Self-Renewal to Specify Endoderm
- (2014) William B. Hamilton et al. Cell Reports
- Intrinsic Resistance to MEK Inhibition in KRAS Mutant Lung and Colon Cancer through Transcriptional Induction of ERBB3
- (2014) Chong Sun et al. Cell Reports
- NANOG Is Multiply Phosphorylated and Directly Modified by ERK2 and CDK1 In Vitro
- (2014) Justin Brumbaugh et al. Stem Cell Reports
- Destabilization of KLF10, a tumor suppressor, relies on thr93 phosphorylation and isomerase association
- (2013) Yu-Chyi Hwang et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH
- PGC1α Expression Defines a Subset of Human Melanoma Tumors with Increased Mitochondrial Capacity and Resistance to Oxidative Stress
- (2013) Francisca Vazquez et al. CANCER CELL
- Enhanced Inhibition of ERK Signaling by a Novel Allosteric MEK Inhibitor, CH5126766, That Suppresses Feedback Reactivation of RAF Activity
- (2013) Nobuya Ishii et al. CANCER RESEARCH
- Discovery of a Selective Kinase Inhibitor (TAK-632) Targeting Pan-RAF Inhibition: Design, Synthesis, and Biological Evaluation of C-7-Substituted 1,3-Benzothiazole Derivatives
- (2013) Masanori Okaniwa et al. JOURNAL OF MEDICINAL CHEMISTRY
- Phosphorylation of BRAF by AMPK Impairs BRAF-KSR1 Association and Cell Proliferation
- (2013) Che-Hung Shen et al. MOLECULAR CELL
- Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers
- (2013) Georgia Hatzivassiliou et al. NATURE
- Control of cell cycle transcription during G1 and S phases
- (2013) Cosetta Bertoli et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- ERK and AKT signaling cooperate to translationally regulate survivin expression for metastatic progression of colorectal cancer
- (2013) Q Ye et al. ONCOGENE
- Selective RAF inhibitor impairs ERK1/2 phosphorylation and growth in mutant NRAS, vemurafenib-resistant melanoma cells
- (2013) Kaitlyn Le et al. Pigment Cell & Melanoma Research
- Ablation of BRaf Impairs Neuronal Differentiation in the Postnatal Hippocampus and Cerebellum
- (2013) Verena Pfeiffer et al. PLoS One
- MAPK Signaling Pathway Regulates p27 Phosphorylation at Threonin 187 as Part of the Mechanism Triggered by Early-Weaning to Induce Cell Proliferation in Rat Gastric Mucosa
- (2013) Luciana H. Osaki et al. PLoS One
- Stimulation of de Novo Pyrimidine Synthesis by Growth Signaling Through mTOR and S6K1
- (2013) I. Ben-Sahra et al. SCIENCE
- Dual Inactivation of Akt and ERK by TIC10 Signals Foxo3a Nuclear Translocation, TRAIL Gene Induction, and Potent Antitumor Effects
- (2013) J. E. Allen et al. Science Translational Medicine
- Discovery of Dabrafenib: A Selective Inhibitor of Raf Kinases with Antitumor Activity against B-Raf-Driven Tumors
- (2013) Tara R. Rheault et al. ACS Medicinal Chemistry Letters
- Discovery of a Novel ERK Inhibitor with Activity in Models of Acquired Resistance to BRAF and MEK Inhibitors
- (2013) E. J. Morris et al. Cancer Discovery
- Synthetic Lethal Interaction of Combined BCL-XL and MEK Inhibition Promotes Tumor Regressions in KRAS Mutant Cancer Models
- (2012) Ryan B. Corcoran et al. CANCER CELL
- RSK2 as a key regulator in human skin cancer
- (2012) Yong-Yeon Cho et al. CARCINOGENESIS
- Dynamic Reprogramming of the Kinome in Response to Targeted MEK Inhibition in Triple-Negative Breast Cancer
- (2012) James S. Duncan et al. CELL
- MYC on the Path to Cancer
- (2012) Chi V. Dang CELL
- Oncogenic Kras Maintains Pancreatic Tumors through Regulation of Anabolic Glucose Metabolism
- (2012) Haoqiang Ying et al. CELL
- Src tyrosine kinase inhibits apoptosis through the Erk1/2- dependent degradation of the death accelerator Bik
- (2012) J Lopez et al. CELL DEATH AND DIFFERENTIATION
- Programmed cell death pathways in cancer: a review of apoptosis, autophagy and programmed necrosis
- (2012) L. Ouyang et al. CELL PROLIFERATION
- Targeting the MAPK–RAS–RAF signaling pathway in cancer therapy
- (2012) Libero Santarpia et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- SEL-10/Fbw7-dependent negative feedback regulation of LIN-45/Braf signaling in C. elegans via a conserved phosphodegron
- (2012) C. de la Cova et al. GENES & DEVELOPMENT
- Abrogation of BRAFV600E-induced senescence by PI3K pathway activation contributes to melanomagenesis
- (2012) L. C. W. Vredeveld et al. GENES & DEVELOPMENT
- The intermediate-activity L597VBRAF mutant acts as an epistatic modifier of oncogenic RAS by enhancing signaling through the RAF/MEK/ERK pathway
- (2012) C. Andreadi et al. GENES & DEVELOPMENT
- Ring Finger Protein 149 Is an E3 Ubiquitin Ligase Active on Wild-type v-Raf Murine Sarcoma Viral Oncogene Homolog B1 (BRAF)
- (2012) Seung-Woo Hong et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Serine 111 Phosphorylation Regulates OCT4A Protein Subcellular Distribution and Degradation
- (2012) Renza Spelat et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- PGC1 and mitochondrial metabolism - emerging concepts and relevance in ageing and neurodegenerative disorders
- (2012) S. Austin et al. JOURNAL OF CELL SCIENCE
- CEP-32496: A Novel Orally Active BRAFV600E Inhibitor with Selective Cellular and In Vivo Antitumor Activity
- (2012) J. James et al. MOLECULAR CANCER THERAPEUTICS
- ERK1/2-dependent phosphorylation and nuclear translocation of PKM2 promotes the Warburg effect
- (2012) Weiwei Yang et al. NATURE CELL BIOLOGY
- ERK1 and ERK2 regulate embryonic stem cell self-renewal through phosphorylation of Klf4
- (2012) Myoung Ok Kim et al. NATURE STRUCTURAL & MOLECULAR BIOLOGY
- MEK Is a Key Regulator of Gliogenesis in the Developing Brain
- (2012) Xiaoyan Li et al. NEURON
- Progression of RAS-Mutant Leukemia during RAF Inhibitor Treatment
- (2012) Margaret K. Callahan et al. NEW ENGLAND JOURNAL OF MEDICINE
- ERK1/2 MAP kinases: Structure, function, and regulation
- (2012) Robert Roskoski PHARMACOLOGICAL RESEARCH
- ERK2 phosphorylation of serine 77 regulates Bmf pro-apoptotic activity
- (2012) Y Shao et al. Cell Death & Disease
- Melanoma whole-exome sequencing identifies V600E B-RAF amplification-mediated acquired B-RAF inhibitor resistance
- (2012) Hubing Shi et al. Nature Communications
- The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data: Figure 1.
- (2012) Ethan Cerami et al. Cancer Discovery
- MEK1/2 dual-specificity protein kinases: Structure and regulation
- (2011) Robert Roskoski BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Discovery of TAK-733, a potent and selective MEK allosteric site inhibitor for the treatment of cancer
- (2011) Qing Dong et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Design and synthesis of novel allosteric MEK inhibitor CH4987655 as an orally available anticancer agent
- (2011) Yoshiaki Isshiki et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- p90RSK2 is essential for FLT3-ITD- but dispensable for BCR-ABL-induced myeloid leukemia
- (2011) S. Elf et al. BLOOD
- Hallmarks of Cancer: The Next Generation
- (2011) Douglas Hanahan et al. CELL
- GSK1120212 (JTP-74057) Is an Inhibitor of MEK Activity and Activation with Favorable Pharmacokinetic Properties for Sustained In Vivo Pathway Inhibition
- (2011) A. G. Gilmartin et al. CLINICAL CANCER RESEARCH
- Killing the second messenger: targeting loss of cell cycle control in endocrine-resistant breast cancer
- (2011) C. A. Lange et al. ENDOCRINE-RELATED CANCER
- Inhibition of Ras for cancer treatment: the search continues
- (2011) Antonio T Baines et al. Future Medicinal Chemistry
- Mitogen-activated Protein Kinase Kinase 1 (MEK1) Stabilizes MyoD through Direct Phosphorylation at Tyrosine 156 During Myogenic Differentiation
- (2011) Chulman Jo et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Comparative Metabolic Flux Profiling of Melanoma Cell Lines
- (2011) David A. Scott et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- BAD Contributes to RAF-mediated Proliferation and Cooperates with B-RAF-V600E in Cancer Signaling
- (2011) Lisa Polzien et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- RASMutations Are Associated With the Development of Cutaneous Squamous Cell Tumors in Patients Treated With RAF Inhibitors
- (2011) Patrick A. Oberholzer et al. JOURNAL OF CLINICAL ONCOLOGY
- Design and Optimization of Potent and Orally Bioavailable Tetrahydronaphthalene Raf Inhibitors
- (2011) Alexandra E. Gould et al. JOURNAL OF MEDICINAL CHEMISTRY
- ERK-MAPK Drives Lamellipodia Protrusion by Activating the WAVE2 Regulatory Complex
- (2011) Michelle C. Mendoza et al. MOLECULAR CELL
- Regulation of Primary Response Genes
- (2011) Trent Fowler et al. MOLECULAR CELL
- Oncogenic K-Ras decouples glucose and glutamine metabolism to support cancer cell growth
- (2011) D. Gaglio et al. Molecular Systems Biology
- RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)
- (2011) Poulikos I. Poulikakos et al. NATURE
- Regulating the regulator: post-translational modification of RAS
- (2011) Ian M. Ahearn et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- The Raf kinase inhibitor PLX5568 slows cyst proliferation in rat polycystic kidney disease but promotes renal and hepatic fibrosis
- (2011) B. Buchholz et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
- Resistance to MEK Inhibitors: Should We Co-Target Upstream?
- (2011) P. I. Poulikakos et al. Science Signaling
- Inhibition of extracellular signal-regulated kinase (ERK) activity with SL327 does not prevent acquisition, expression, and extinction of ethanol-seeking behavior in mice
- (2010) Peter A. Groblewski et al. BEHAVIOURAL BRAIN RESEARCH
- RAF protein-serine/threonine kinases: Structure and regulation
- (2010) Robert Roskoski BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- The Resorcylic Acid Lactone Hypothemycin Selectively Inhibits the Mitogen-Activated Protein Kinase Kinase-Extracellular Signal-Regulated Kinase Pathway in Cells
- (2010) Hidesuke Fukazawa et al. BIOLOGICAL & PHARMACEUTICAL BULLETIN
- Blockade of the MEK/ERK signalling cascade by AS703026, a novel selective MEK1/2 inhibitor, induces pleiotropic anti-myeloma activity in vitro and in vivo
- (2010) Kihyun Kim et al. BRITISH JOURNAL OF HAEMATOLOGY
- Cell Signaling by Receptor Tyrosine Kinases
- (2010) Mark A. Lemmon et al. CELL
- Small-Molecule Inhibitors of the ERK Signaling Pathway: Towards Novel Anticancer Therapeutics
- (2010) Jeremy L. Yap et al. ChemMedChem
- Genetic analysis of Ras signalling pathways in cell proliferation, migration and survival
- (2010) Matthias Drosten et al. EMBO JOURNAL
- Role of Ras/Raf/MEK/ERK signaling in physiological hematopoiesis and leukemia development
- (2010) Eva Chung et al. IMMUNOLOGIC RESEARCH
- Regorafenib (BAY 73-4506): A new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity
- (2010) Scott M. Wilhelm et al. INTERNATIONAL JOURNAL OF CANCER
- ERK1/2 Phosphorylate Raptor to Promote Ras-dependent Activation of mTOR Complex 1 (mTORC1)
- (2010) Audrey Carriere et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- p90 ribosomal S6 kinase 2 promotes invasion and metastasis of human head and neck squamous cell carcinoma cells
- (2010) Sumin Kang et al. JOURNAL OF CLINICAL INVESTIGATION
- The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Oral Doses of RO5068760, an MEK Inhibitor, in Healthy Volunteers: Assessment of Target Suppression
- (2010) Lucy Lee et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Genetic Demonstration of a Redundant Role of Extracellular Signal-Regulated Kinase 1 (ERK1) and ERK2 Mitogen-Activated Protein Kinases in Promoting Fibroblast Proliferation
- (2010) L. Voisin et al. MOLECULAR AND CELLULAR BIOLOGY
- Dependence on Phosphoinositide 3-Kinase and RAS-RAF Pathways Drive the Activity of RAF265, a Novel RAF/VEGFR2 Inhibitor, and RAD001 (Everolimus) in Combination
- (2010) P. Mordant et al. MOLECULAR CANCER THERAPEUTICS
- RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF
- (2010) Poulikos I. Poulikakos et al. NATURE
- Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma
- (2010) Gideon Bollag et al. NATURE
- Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation
- (2010) Ramin Nazarian et al. NATURE
- The landscape of somatic copy-number alteration across human cancers
- (2010) Rameen Beroukhim et al. NATURE
- Cell adhesion: integrating cytoskeletal dynamics and cellular tension
- (2010) J. Thomas Parsons et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Linking actin dynamics and gene transcription to drive cellular motile functions
- (2010) Eric N. Olson et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- c-MYC coordinately regulates ribosomal gene chromatin remodeling and Pol I availability during granulocyte differentiation
- (2010) Gretchen Poortinga et al. NUCLEIC ACIDS RESEARCH
- COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer
- (2010) S. A. Forbes et al. NUCLEIC ACIDS RESEARCH
- BRAF Gene Amplification Can Promote Acquired Resistance to MEK Inhibitors in Cancer Cells Harboring the BRAF V600E Mutation
- (2010) R. B. Corcoran et al. Science Signaling
- Non-hinge-binding pyrazolo[1,5-a]pyrimidines as potent B-Raf kinase inhibitors
- (2009) Dan M. Berger et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Phosphorylated ERK is a potential predictor of sensitivity to sorafenib when treating hepatocellular carcinoma: evidence from an in vitrostudy
- (2009) Zhe Zhang et al. BMC Medicine
- Antitumor Efficacy of the Novel RAF Inhibitor GDC-0879 Is Predicted by BRAFV600E Mutational Status and Sustained Extracellular Signal-Regulated Kinase/Mitogen-Activated Protein Kinase Pathway Suppression
- (2009) K. P. Hoeflich et al. CANCER RESEARCH
- PI3K Pathway Activation Mediates Resistance to MEK Inhibitors in KRAS Mutant Cancers
- (2009) S. Wee et al. CANCER RESEARCH
- Extracellular Signal-Regulated Kinase Signaling Pathway Regulates Breast Cancer Cell Migration by Maintaining slug Expression
- (2009) H. Chen et al. CANCER RESEARCH
- RDEA119/BAY 869766: A Potent, Selective, Allosteric Inhibitor of MEK1/2 for the Treatment of Cancer
- (2009) C. Iverson et al. CANCER RESEARCH
- Phosphorylation of the Human MicroRNA-Generating Complex Mediates MAPK/Erk Signaling
- (2009) Zain Paroo et al. CELL
- A Systems Perspective of Ras Signaling in Cancer
- (2009) E. C. Stites et al. CLINICAL CANCER RESEARCH
- Isoform-specific ras functions in development and cancer
- (2009) Margaret P Quinlan et al. Future Oncology
- Identification and Functional Characterization of ERK/MAPK Phosphorylation Sites in the Runx2 Transcription Factor
- (2009) Chunxi Ge et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- E6201 [(3S,4R,5Z,8S,9S,11E)-14-(Ethylamino)-8, 9,16-trihydroxy-3,4-dimethyl-3,4,9,19-tetrahydro-1H-2-benzoxacyclotetradecine-1,7(8H)-dione], a Novel Kinase Inhibitor of Mitogen-Activated Protein Kinase/Extracellular Signal-Regulated Kinase Kinase (MEK)-1 and MEK Kinase-1: In Vitro Characterization of Its Anti-Inflammatory and Antihyperproliferative Activities
- (2009) M. Goto et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- Impact of Feedback Phosphorylation and Raf Heterodimerization on Normal and Mutant B-Raf Signaling
- (2009) D. A. Ritt et al. MOLECULAR AND CELLULAR BIOLOGY
- Oncogenic B-RAF Negatively Regulates the Tumor Suppressor LKB1 to Promote Melanoma Cell Proliferation
- (2009) Bin Zheng et al. MOLECULAR CELL
- BrafV600E cooperates with Pten loss to induce metastatic melanoma
- (2009) David Dankort et al. NATURE GENETICS
- A Mek1–Mek2 heterodimer determines the strength and duration of the Erk signal
- (2009) Federica Catalanotti et al. NATURE STRUCTURAL & MOLECULAR BIOLOGY
- MEK1 mutations confer resistance to MEK and B-RAF inhibition
- (2009) C. M. Emery et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Corynoxeine Isolated from the Hook of Uncaria rhynchophylla Inhibits Rat Aortic Vascular Smooth Muscle Cell Proliferation through the Blocking of Extracellular Signal Regulated Kinase 1/2 Phosphorylation
- (2008) Tack-Joong Kim et al. BIOLOGICAL & PHARMACEUTICAL BULLETIN
- The identification of potent, selective and CNS penetrant furan-based inhibitors of B-Raf kinase
- (2008) Andrew K. Takle et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- The discovery of the benzhydroxamate MEK inhibitors CI-1040 and PD 0325901
- (2008) Stephen D. Barrett et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Elevated CRAF as a Potential Mechanism of Acquired Resistance to BRAF Inhibition in Melanoma
- (2008) C. Montagut et al. CANCER RESEARCH
- ERK-dependent threonine phosphorylation of EGF receptor modulates receptor downregulation and signaling
- (2008) Xin Li et al. CELLULAR SIGNALLING
- Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E-mutated melanomas
- (2008) K. S.M. Smalley et al. MOLECULAR CANCER THERAPEUTICS
- Multisite Phosphorylation Regulates Bim Stability and Apoptotic Activity
- (2008) Anette Hübner et al. MOLECULAR CELL
- ERK promotes tumorigenesis by inhibiting FOXO3a via MDM2-mediated degradation
- (2008) Jer-Yen Yang et al. NATURE CELL BIOLOGY
- CRAF inhibition induces apoptosis in melanoma cells with non-V600E BRAF mutations
- (2008) K S M Smalley et al. ONCOGENE
- Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity
- (2008) J. Tsai et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now